Amino-functionalized nanoparticles as inhibitors of mTOR and inducers of cell cycle arrest in leukemia cells

Biomaterials

Volumn 35, Issue 6, 2014, Pages 1944-1953

  Loos, Cornelia ^a   Syrovets, Tatiana ^a   Musyanovych, Anna ^b   Mailänder, Volker ^b,c   Landfester, Katharina ^b   Simmet, Thomas ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Amino functionalization; Apoptosis; Carboxyl functionalization; Leukemia; MTOR signaling; Polystyrene nanoparticles

Indexed keywords

ANTIBIOTICS; CELL CULTURE; CELL DEATH; CHEMICAL ACTIVATION; DISEASES; MAMMALS; NANOPARTICLES; POLYSTYRENES; SIGNALING; TARGETED DRUG DELIVERY;

AMINO FUNCTIONALIZATION; FUNCTIONALIZATIONS; LEUKEMIA; MTOR SIGNALING; POLYSTYRENE NANOPARTICLES;

CELL SIGNALING;

AMINO FUNCTIONALIZED POLYSTYRENE NANOPARTICLE; CARBOXY FUNCTIONALIZED POLYSTYRENE NANOPARTICLE; CARBOXYL GROUP; CATHEPSIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NANOPARTICLE; POLYSTYRENE; PROCATHEPSIN B; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE ARREST; CELL ORGANELLE; CELL PERMEABILIZATION; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MACROPHAGE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR XENOGRAFT;

MAMMALIA;

AMINO FUNCTIONALIZATION; APOPTOSIS; CARBOXYL FUNCTIONALIZATION; LEUKEMIA; MTOR SIGNALING; POLYSTYRENE NANOPARTICLES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; HUMANS; LEUKEMIA; NANOPARTICLES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890150208     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.056     Document Type: Article

References (33)

1. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
2. Lunov O., Syrovets T., Loos C., Beil J., Delacher M., Tron K., et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 2011, 5:1657-1669.
3. Lunov O., Syrovets T., Röcker C., Tron K., Nienhaus G.U., Rasche V., et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010, 31:9015-9022.
4. Lunov O., Zablotskii V., Syrovets T., Röcker C., Tron K., Nienhaus G.U., et al. Modeling receptor-mediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. Biomaterials 2010, 32:547-555.
5. Stern S.T., Adiseshaiah P.P., Crist R.M. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol 2012, 9:20.
6. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005, 5:886-897.
7. Kallunki T., Olsen O.D., Jäättelä M. Cancer-associated lysosomal changes: friends or foes?. Oncogene 2012, 32:1995-2004.
8. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.
9. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008, 11:63-76.
10. Teachey D.T., Grupp S.A., Brown V.I. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009, 145:569-580.
11. Xia T., Kovochich M., Liong M., Zink J.I., Nel A.E. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano 2008, 2:85-96.
12. Lunov O., Syrovets T., Loos C., Nienhaus G.U., Mailänder V., Landfester K., et al. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano 2011, 5:9648-9657.
13. Musyanovych A., Rossmanith R., Tontsch C., Landfester K. Effect of hydrophilic comonomer and surfactant type on the colloidal stability and size distribution of carboxyl- and amino-functionalized polystyrene particles prepared by miniemulsion polymerization. Langmuir 2007, 23:5367-5376.
14. Lunov O., Syrovets T., Büchele B., Jiang X., Röcker C., Tron K., et al. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 2010, 31:5063-5071.
15. Syrovets T., Jendrach M., Rohwedder A., Schüle A., Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKβ-mediated NF-κB activation. Blood 2001, 97:3941-3950.
16. Burysek L., Syrovets T., Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. JBiol Chem 2002, 277:33509-33517.
17. Syrovets T., Gschwend J.E., Büchele B., Laumonnier Y., Zugmaier W., Genze F., et al. Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells invitro and invivo. JBiol Chem 2005, 280:6170-6180.
18. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381:484-495.
19. Li X., Syrovets T., Genze F., Pitterle K., Oberhuber A., Orend K.H., et al. Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. Arterioscler Thromb Vasc Biol 2010, 30:582-590.
20. Estrada A.C., Syrovets T., Pitterle K., Lunov O., Büchele B., Schimana-Pfeifer J., et al. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387.
21. Morad S.A., Schmid M., Büchele B., Siehl H.U., El Gafaary M., Lunov O., et al. Anovel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells. Mol Pharmacol 2013, 83:531-541.
22. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
23. Rozman J., Stojan J., Kuhelj R., Turk V., Turk B. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett 1999, 459:358-362.
24. Copp J., Manning G., Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009, 69:1821-1827.
25. Gillis L.D., Leidal A.M., Hill R., Lee P.W. p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle 2009, 8:253-256.
26. Park M., Chae H.D., Yun J., Jung M., Kim Y.S., Kim S.H., et al. Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 2000, 60:542-545.
27. Park S., Chapuis N., Tamburini J., Bardet V., Cornillet-Lefebvre P., Willems L., et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010, 95:819-828.
28. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009, 69:2425-2434.
29. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth invitro and invivo. Cancer Res 2008, 68:7956-7965.
30. Ogmundsdottir M.H., Heublein S., Kazi S., Reynolds B., Visvalingam S.M., Shaw M.K., et al. Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes. PLoS One 2012, 7:e36616.
31. Thomas T.P., Majoros I., Kotlyar A., Mullen D., Holl M.M., Baker J.R. Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. Biomacromolecules 2009, 10:3207-3214.
32. Yu L., McPhee C.K., Zheng L., Mardones G.A., Rong Y., Peng J., et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
33. Bove J., Martinez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011, 12:437-452.